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ABSTRACT 
Background: Several epidermal growth factor receptor (EGFR) inhibitors have been 
successfully developed for the treatment of cancer, limiting tumor growth and metastasis. EGFR 
is also expressed by leukocytes, but little is known about its role in the modulation of the 
immune response.  
Objectives: We aimed to determine whether EGFR expressed on CD4
+
 T cells is functional, and 
to address the consequences of EGFR inhibition in atherosclerosis, a T cell-mediated vascular 
chronic inflammatory disease. 
Methods and. Mouse CD4
+
 T cells expressed EGFR, and the EGFR tyrosine kinase inhibitor 
AG-1478 blocked in vitro T cell proliferation and Th1/Th2 cytokine production.  
Results: In vivo, treatment of Ldlr
-/-
 mice with the EGFR inhibitor Erlotinib induced T cell 
anergy, reduced T cell infiltration within atherosclerotic lesions and protected against 
atherosclerosis development and progression. Selective deletion of EGFR in CD4
+
 T cells 
resulted in decreased T cell proliferation and activation both in vitro and in vivo, as well as 
reduced IFN-, IL-4, IL-2 production. Atherosclerotic lesion size was reduced by 2-fold in 
irradiated Ldlr
-/-
 mice reconstituted with bone marrow from Cd4-Cre/Egfr
lox/lox
 mouse, compared 
to Cd4-Cre/Egfr
+/+ 
chimeric
 
mice, after 4, 6 and 12 weeks of high fat diet, associated with 
marked reduction in T cell infiltration in atherosclerotic plaques. Human blood T cells expressed 
EGFR and EGFR inhibition reduced T cell proliferation both in vitro and in vivo. 
Conclusions. EGFR blockade induced T cell anergy in vitro and in vivo, and reduced 
atherosclerosis development. Targeting EGFR may be a novel strategy to combat atherosclerosis. 
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Condensed Abstract: CD4
+
 T cell adaptive immunity, in response to lipoprotein accumulation 
in the arterial wall, is involved in the development of atherosclerosis. Using several 
complementary approaches, we identified for the first time a critical role of EGFR in CD4
+
 T 
cell homeostasis, in both mice and humans. EGFR genetic invalidation or pharmacological 
blockade impaired T cell activation, proliferation, cytokine production and reduced both 
atherosclerosis development and progression. Our findings indicate that EGFR inhibitors, widely 
used in patients with cancer, are unlikely to worsen the risk of cardiovascular disease, and even 
more suggest that EGFR may constitute a novel therapeutic target in atherosclerosis-related 
diseases. 
 
Abbreviations 
CD, Cluster of Differentiation 
EGF, Epidermal Growth factor 
IL-, Interleukin 
LDL, Low Density Lipoprotein 
Th, T Helper 
TKI, tyrosine kinase inhibitors   
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Introduction 
Epidermal Growth Factor Receptor (EGFR) is a cell membrane-bound receptor with 
tyrosine kinase activity involved in the control of major signaling pathways, including cell 
survival, proliferation and migration. EGFR overexpression, autocrine ligand stimulation, or 
constitutively active receptor mutants (1,2) can lead to dysregulation of this fine-tuned signaling 
system, resulting in a variety of pathophysiological disorders and promoting cancer 
development. Six EGFR ligands have been described, including Epidermal Growth Factor 
(EGF), Heparin Binding-Epidermal Growth Factor (HB-EGF), Amphiregulin and Transforming 
Growth Factor-. Extracellular ligand binding causes dimerisation of EGFR, which becomes 
autophosphorylated at distinct tyrosine residues. In addition, EGFR could be transactivated in the 
absence of a specific ligand through G-protein-coupled receptor activation (3). 
EGFR has been extensively explored in cancer. Human and experimental studies showed 
that EGFR activation on tumor cells ultimately leads to cell proliferation, invasion, and 
migration, as well as promoting angiogenesis and inhibiting apoptosis (4). Targeting of EGFR by 
either neutralizing monoclonal antibodies or small-molecule tyrosine kinase inhibitors (TKI) 
have been shown during the last ten years to be a successful therapeutic strategy in cancer setting 
(5,6). However, EGFR expression and functions have been poorly investigated in non-tumoral 
cells. Some authors described an expression in circulating leucocytes (7,8) but little is known 
about its role in the modulation of the immune response. 
Atherosclerosis is an inflammatory disease driven by innate and adaptive immunity, in 
which CD4
+
 T cells play a pathogenic role. Interestingly, EGFR ligands, including HB-EGF 
have been detected in human atherosclerotic plaques (9). The aim of this study was to ascertain 
the expression of EGFR in human and mouse CD4
+
 T cells, and to investigate the effects of 
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EGFR blockade on CD4
+
 T cell functions using pharmacological inhibitors and cell-specific 
genetic deletion in mouse models of atherosclerosis. 
Methods 
Animals 
Experiments were conducted according to the guidelines formulated by the European 
Community for experimental animal use (L358-86/609EEC), and were approved by the Ethical 
Committee of INSERM and the French Ministry of Agriculture (agrement no. A75-15-32). To 
generate a cell-specific knockout of Egfr in CD4
+
 T cells, we crossbred mice carrying a Cd4Cre 
allele with mice carrying a floxed Egfr allele. All animals have been backcrossed more than ten 
generations on C57bl/6 background. Ten-week old male C57BL/6 Ldlr
-/-
 mice were put on a high 
fat diet for 8 weeks and were treated with the oral (daily gavage), specific EGFR tyrosine kinase 
inhibitor, erlotinib (15mg/kg/day). For bone marrow transplantation experiments, 10-week old 
male C57bl/6 Ldlr
-/-
 mice were subjected to medullar aplasia by lethal total body irradiation (9.5 
grays). The mice were repopulated with an intravenous injection of bone marrow cells isolated 
from femurs and tibias of sex-matched C57BL/6 Cd4Cre Egfr
+/+
 mice or Cd4Cre Egfr
lox/lox
 
littermates. After 4 weeks of recovery, mice were fed a pro-atherogenic diet containing 15% fat, 
1.25% cholesterol and 0% cholate for 4, 6, and 12 weeks.  
Extent and composition of atherosclerotic lesions 
Plasma cholesterol was measured using a commercial cholesterol kit (Biomérieux). The 
heart of mice was removed and successive 10-µm transversal sections of aortic sinus were 
obtained. Lipids were detected using Red Oil staining. The presence of T cells was studied using 
specific antibodies, as previously described (polyclonal anti-CD3, DAKO) (10). Egfr was 
detected in cells and lesions using a rabbit polyclonal anti-Phospho-Egfr (Cell Signaling, Boston, 
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USA). For human staining, an anti-EGFR antibody (clone 31G7, AbCys S.A.) was used. At least 
4 sections per mouse were examined for each immunostaining, and appropriate negative controls 
were used. Morphometric studies were performed using Histolab software (Microvisions) (10).  
Spleen cell recovery and purification 
Spleen cells were purified according to standard protocols as follows. CD4
+
 T cells were 
negatively selected using a cocktail of antibody-coated magnetic beads from Miltenyi Biotech 
(anti-CD8a, anti-CD11b, anti-CD45R, anti-DX5, anti-ter 119), according to manufacturer’s 
instructions, yielding CD4
+
 cells with >95% purity. CD11c
+
 cells were positively selected with 
biotin-conjugated anti-CD11c mAb (7D4, PharMingen), streptavidin microbeads (Miltenyi 
Biotec), followed by 2 consecutive magnetic cell separations using LS columns (Miltenyi 
Biotec), yielding CD11c
+
 cells with >80% purity. 
CD4
+
 T cell culture and cytokine assays 
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% FCS, 0.02 mM -
mercaptoethanol and antibiotics. For cytokine measurements, CD4
+
 T cells were cultured at 
1x10
5
 cells/well for 48 hours in anti-CD3-coated microplates (10 g/ml) or with Concanavalin A 
(Sigma, 10 g/ml). In some experiments, CD4+ T cells were stimulated with purified soluble 
CD3-specific antibody (1 g/ml, Pharmingen) in the presence of antigen-presenting cells 
purified on CD11c-coated magnetic beads (Miltenyi Biotech). IL-2, IL-4, IL-10 and IFN- 
productions in the supernatants were measured using specific ELISAs (R&D Systems). 
Other methods (Cell culture, proliferation assays, cytosolic calcium recording, flow 
cytometry and western Blot) are available in the Online Appendix. 
Statistical analysis 
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Values are expressed as median and percentiles (25
th
-75
th
) in the text. Differences 
between values were evaluated using non-parametric Mann-Whitney or Kruskal-Wallis test. 
Values of p<0.05 were considered significant. All these analysis were performed using GraphPad 
Prism version 5.0b for Mac (GraphPad Software). No adjustments were made for multiple pair-
wise comparisons. 
Based on preliminary experiments, we assumed that EGFR blockade induces a 40% 
reduction of atherosclerosis. With a standard deviation of plaque size estimated at 30%, the 
inclusion of 8 mice/group was sufficient to detect a significant difference between groups with 
80% power. 
Results  
EGFR in mouse CD4
+
 T cells: expression and signaling pathways 
Using immunocytostaining, we detected EGFR expression by splenocytes and found that 
EGFR co-localized, non-exclusively, with CD4+ T cells (Figure 1A). In addition, EGFR was 
present in mouse atherosclerotic lesions and co-localized with CD4
+
 T cells (Figure 1B). In 
vitro, anti-CD3- and concanavalin A-induced activation of purified CD4
+
 T cells caused EGFR 
phosphorylation after 60 minutes of stimulation (Figure 1C). AG-1478, a pharmacological 
inhibitor of tyrosine kinase, blocked EGFR phosphorylation in stimulated T cells (Figure 1C) 
and significantly reduced ERK1/2 phosphorylation (Figure 1D, Online Figure 1), but had no 
effect on AKT (Online Figure 1). In addition, we found that EGFR inhibition blocked 
cytoplasmic calcium increase following anti-CD3/CD28 stimulation (Figure 1E). In summary, 
anti-CD3 stimulation of CD4
+
 T cells leads to EGFR transactivation that was efficiently 
inhibited by AG-1478. 
Effects of pharmacological inhibition of EGFR on atherosclerosis 
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To address the role of EGFR on T cell functions, splenic CD4
+
 T cells were purified and 
stimulated in vitro. EGFR activity was inhibited using AG-1478 at different concentrations. 
EGFR inhibition significantly reduced T cell proliferation following non-antigen-specific 
(Figure 2A) and antigen-specific (Figure 2B) stimulation in a dose-dependent manner without 
any effect on T cell apoptosis (Figure 2C) or nucleus-cytoplasm organization (Online Figure 2). 
Pharmacological inhibition of EGFR significantly reduced intracellular IFN- production by 
CD4
+
 T cells in response to anti-CD3 (Figure 2D) and concanavalin stimulation (Figure 2E). 
This was confirmed by ELISA in the supernatants of cultured splenic CD4
+
 T cells, showing that 
EGFR inhibition significantly reduced the production of IFN- (Figure 2 F, G), reduced the 
production of IL-2 (supplemental figure 3), as well as that of IL-4 (Figure 2H), in a dose-
dependent manner, but had no effect on IL-10 production that was very low (Figure 2I). 
To investigate the in vivo consequences of EGFR pharmacological inhibition, Ldlr
-/-
 male 
mice were put on a high fat diet during 8 weeks and were orally treated with erlotinib 
(15mg/kg/day) (Figure 3A). At sacrifice, animal weight (Online Figure 4A) and plasma 
cholesterol level (Figure 3B) were not different between groups, but there was a significant 
reduction of spleen size (supplemental figure 4B) and splenocyte number (Figure 3C) in the 
erlotinib-treated group. Splenic CD4
+
 T cells from erlotinib-treated group
 
were characterized by 
a significant decrease in CD25 (Online Figure 5A) and CD44
high
 expression (Supplemental 
figure 5B), suggesting reduced in vivo activation. Erlotinib had no effect on 
CD4
+
CD25
high
Foxp3
+
 regulatory T cell population (Online Figure 5C). Splenic purified CD4
+
 T 
cells from erlotinib-treated group were characterized by a reduction of proliferation ex vivo 
(Figure 3D) and a reduction of Th1 (IFN-) and Th2 (IL-4) cytokine production with no effect 
on IL-10 (Figure 3E). Immunohistochemistry analysis revealed that erlotinib treatment induced 
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a 70% reduction of T cell infiltration within atherosclerotic lesions (P=0.01) (Figure 3F), which 
was associated with 37% reduction of atherosclerotic lesion size in the aortic sinus (167 [91-190] 
x10
3
 in treated mice versus 267 [180-333] x10
3
 m2 in control mice, P<0.05) (Figure 3G). 
In the vast majority of cases, patients in need of an anti-atherosclerotic therapy already 
have established atherosclerotic plaques. Thus, we examined the effects of EGFR blockade on 
the progression of established atherosclerotic plaques in mice. Six-week old Ldlr
-/-
 female mice 
were put on a high fat diet during 8 weeks and then were orally treated with a placebo or 
erlotinib (15mg/kg/day) during 8 weeks (Figure 3H). At sacrifice, animal weight (data not 
shown) and plasma cholesterol levels (Online Figure 6C) were not different between groups. In 
Erlotinib-treated group, we observed a marked reduction in atherosclerotic lesion size both in the 
aortic sinus (176 [159-218] x10
3
 versus 269 [193-343] x10
3
 m2, P<0.05) (Online Figure 6A & 
6B) and along the thoracic aorta (14.0 [12.4-14.9] versus 20.7 [15.2-22.3] %, P<0.05) (Figure 
3I). More importantly, atherosclerosis plaque size increased between baseline 14-week old mice 
and 22-week old mice in the placebo group, but did not progress in the group receiving Erlotinib 
(Figure 3I and Online Figure 6), suggesting that Erlotinib treatment blocked atherosclerosis 
progression. 
EGFR in human CD4
+
 T cells: expression and functions 
To evaluate the clinical relevance of our findings, we investigated the expression of 
EGFR in human blood T cells. We performed immunocytostaining of purified blood CD4+ T 
cells and found that EGFR was expressed and clustered in the membrane of CD4
+
 T cells after 
Concanavalin-induced activation (Figure 4A). To investigate the functions of human EGFR, we 
purified circulating CD4+ T cells from healthy donors and performed in vitro proliferation tests. 
CD3/CD28-coated beads stimulation induced T cell proliferation and EGFR inhibition using 
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AG-1478 or Cetuximab, an EGFR neutralizing mAb, significantly decreased T cell proliferation 
(Figure 4B & 4C). This result was confirmed in vivo in patients with lung cancer. Circulating T 
cells were isolated from 3 patients before and one month after oral erlotinib treatment. 
Interestingly, T cell proliferation was lower after erlotinib treatment (Figure 4D). 
Cell-specific genetic invalidation of Egfr in CD4
+
 T cells 
Erlotinib administration induced T cell anergy and reduced atherosclerosis development. 
As the expression of EGFR is ubiquitous, we next assessed the specific role of EGFR activation 
in CD4
+
 T cells in erlotinib-induced atheroprotection. We bred mice carrying a Cd4-Cre allele 
with mice carrying a floxed Egfr allele and generated Cd4-Cre/Egfr
lox/lox
 mice. The deletion of 
EGFR specifically in CD4
+
 T cells was confirmed by immunocytostaining (Online Figure 7). We 
purified splenic CD4
+
 T cells from control Cd4-Cre/Egfr
+/+
 and Cd4-Cre/Egfr
lox/lox
 mice and 
performed functional tests. In vitro, in agreement with experiments using AG-1478, proliferation 
of CD4
+
 T cells from Cd4Cre Egfr
lox/lox
 mice was significantly decreased compared with wild-
type cells (Figure 5A), and their production of Th1 (Figure 5B) and Th2 (Figure 5C) cytokines 
was reduced. There was no difference in IL-10 production (Figure 5D). Similar reduction in cell 
proliferation and cytokine production was observed when EGFR-deficient CD4
+ 
T cells were co-
incubated with CD11c
+
 antigen presenting cells (Figure 5A-D). Intracellular staining by flow 
cytometry confirmed the specific reduction of IFN- production by CD4+ (Figure 5E) but no by 
CD8
+ 
T cells. Apoptosis susceptibility was significantly lower in EGFR-deficient CD4
+
 T cells 
(Online Figure 8). To address the in vivo role of EGFR in CD4
+
 T cell proliferation, we 
transferred into Apoe
-/-
/Rag2
-/-
 mice 20.10
6
 CD4
+
 T cell–depleted splenocytes resupplemented 
with 8.10
6 
purified CFSE-labeled CD4
+
 T cells from either Cd4-Cre/Egfr
+/+ 
or Cd4-Cre/Egfr
lox/lox
 
mice. The proliferation of adoptively transferred cells was visualized by flow cytometric analysis 
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of CFSE-labeled CD4
+
 T cells.  At day 10 after transfer, we found that CD4
+
 T specific deletion 
of EGFR limited T cell proliferation in the spleen and lymph nodes (Figure 5F). 
Impact of CD4
+
 T cell specific invalidation of Egfr on atherosclerosis 
To address the consequences of these findings in the context of atherosclerosis, we 
performed bone marrow transplantation experiments using either Cd4-Cre/Egfr
+/+
 or Cd4-
Cre/Egfr
lox/lox
 littermate bone marrow to repopulate lethally irradiated Ldlr
-/-
 mice. After 4 weeks 
of recovery and additional 4 weeks on high fat diet, animals were sacrified. We did not observe 
any difference in animal or spleen weights, but a 32% reduction in the number of splenocytes in 
chimeric Cd4-Cre/Egfr
lox/lox
 group (P=0.05). Leukocyte populations (neutrophils, monocytes, B 
cells, CD8
+
 T cells) were not different between groups, either in the blood or in the spleen (data 
not shown). Splenic CD4
+
 T cell subset was not different between chimeric Cd4-
Cre/Egfr
+/+
/Ldlr
-/-
 and Cd4-Cre/Egfr
lox/lox
/Ldlr
-/- 
mice (Figure 6A) but the CD4
+
CD25
high
FoxP3
+
 
regulatory T cell (Tregs) population was slightly reduced in the group with CD4 specific deletion 
of EGFR (-14%, P<0.05; Figure 6B). Splenic CD4
+
 T cells from Cd4-Cre/Egfr
lox/lox
/Ldlr
-/- 
were 
characterized by a significant decrease in CD69 (Figure 6C) and CD44
high
 expression (Figure 
6D), suggesting reduced in vivo activation. Functional tests were performed ex vivo in purified 
splenic CD4
+
 T cells. The suppressive function of Tregs was preserved in Cd4-
Cre/Egfr
lox/lox
/Ldlr
-/-
 mice (Figure 6E) but the proliferation of CD4
+
 T cells in response to CD3 
stimulation was reduced compared to cells from control group (figure 6F). Finally, we also 
observed a > 2-fold decrease in IFN- and IL-4 production in the supernatant of anti-CD3-
stimulated CD4
+
 T cells from Cd4-Cre/Egfr
lox/lox
/Ldlr
-/- 
mice compared with Cd4-
Cre/Egfr
+/+
/Ldlr
-/- 
mice (Figure 6G). 
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As shown in Figure 7A, after 4 weeks on high fat diet, Egfr invalidation in CD4
+
 T cells 
led to a 36% decrease in atherosclerotic lesion size in the aortic sinus compared with controls (25 
[16-30] x10
3
 m2 vs 34 [31-57] x103 m2 in Cd4-Cre/Egfrlox/lox/Ldlr/ and Cd4-Cre 
Egfr
+/+
/Ldlr
-/-
, respectively, P=0.03). The reduction of atherosclerosis was confirmed after 6 (-
39%, P=0.02) and 12 weeks (-43%, P=0.02) of high fat diet (Figure 7A). There were no 
significant differences in plasma cholesterol levels between the groups (Online Figure 9). 
We finally analyzed T cell infiltration within the lesions. We found a decrease in T cell 
number in lesions of Cd4Cre Egfr
lox/lox Ldlr-/- compared to Cd4Cre Egfr+/+  Ldlr-/- mice 
(Figure 6B) but no difference in macrophage infiltration (Online Figure 10). 
Discussion 
Using several complementary approaches, we identified a critical role of EGFR in CD4
+
 
T cell homeostasis, in both mice and humans. EGFR genetic invalidation or pharmacological 
blockade impaired T cell activation, proliferation, cytokine production and reduced 
atherosclerosis development (Central Illustration).  
Using immunocytostaining and immunohistochemistry, we found that splenic CD4
+
 T 
cells and blood human T cells express EGFR, especially in response to CD3 or concanavalin A 
stimulation. Immunofluorescent staining showed, after anti-CD3 stimulation, that EGFR 
clustered on the cell membrane and was phosphorylated. In addition, tissue T cells within 
atherosclerotic plaques express EGFR. Our results are in line with those of Zaiss et al. who 
detected both Egfr mRNA expression and EGFR protein in purified CD4
+
 T cells (8). 
Our findings indicate that EGFR signaling is crucial in CD4
+
 T cell homeostasis in both 
human and mouse. Pharmacological inhibition using TKIs (AG-1478 or erlotinib), neutralizing 
antibodies or CD4
+
 T cell specific genetic invalidation of Egfr markedly reduced in vitro and in 
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vivo cell proliferation and Th1/Th2/Th17 cytokine production. A similar observation has been 
reported in a mouse model of graft versus host disease with a reduction of Th1 and Th2 cytokine 
production in erlotinib-treated animals (11). In addition, we observed that EGFR 
inhibition/invalidation reduced T cell infiltration within atherosclerotic lesions suggesting a 
modulation of T cell migration. This might be accounted for reduced chemokine production as 
described in a model of skin inflammation, in which TKI treatment decreased Ccl-17, Ccl-21 and 
Ccl-27 production (11). Reduction of T cell infiltration in the vascular wall of Cd4Cre Egf-r 
lox/lox
 
animals might also be due to altered cell motility resulting from impairment of cytoskeleton 
reorganization (12). A large body of evidence in cancer highlighted the role of EGFR signaling 
in epithelial-mesenchymal transition and invasion/migration of normal and malignant epithelial 
cells (13). Recently, Tai et al. showed that EGFR/Src-signaling triggers the tyrosine 
phosphorylation of β4 integrin, which, in turn, activated FAK, a kinase involved in cytoskeleton 
reorganization (14). In our study, we did not observe any side effect due to EGFR blockade, 
including survival of Erlotinib-treated or Cd4 Cre Egfr
lox/lox 
mice. In addition, we did not find any 
difference in weight or infection susceptibility between groups. These observations suggest that 
EGFR inhibition modulates the immune response but does cause full immunosuppression. 
EGFR inhibition/invalidation did not affect cell death susceptibility but induced a global 
CD4
+
 T cell anergy. The mechanisms of anergy induced by EGFR inhibition likely involved 
MAP kinase signaling pathway as suggested by reduced Erk phosphorylation in CD4
+
 T cells 
treated with AG 1478. This is an agreement with studies by Luo et al. showing that erlotinib 
caused G0/G1 arrest and suppressed the phosphorylation of c-Raf, Erk in activated T cells (15). 
We also showed that EGFR pharmacological blockade negatively impacted on intracellular 
calcium signaling in T cells confirming previous reports on cancer context. Bryant et al. showed 
13 
on glioma tumor cell lines that tyrosine kinase inhibitors including erlotinib and gefinitib limited 
the acute cytoplasmic release of calcium from the endoplasmic reticulum in response to EGF 
(16). 
A recent study suggested that EGFR and one of its ligands, amphiregulin, play a specific 
role in Treg suppressive functions. In mouse models of atherosclerosis, Treg deficiency, obtained 
by Foxp3, Cd28 or Cd80/86 genetic invalidation, increased T cell activation and accelerated 
vascular disease (17-19). However, in our study, the genetic invalidation of Egfr in Ldlr
-/-
 
chimeric mouse model had no effect on the suppressive function of Tregs. We only observed a 
slight reduction in Treg pool in chimeric Cd4-Cre/Egfr
lox/lox
/Ldlr
-/-
 compared with Cd4-
Cre/Egfr
+/+
/Ldlr
-/- 
mice. Our results show that EGFR inhibition had a predominant effect on T 
cell anergy and reduced atherosclerosis development. In vitro, we challenged T cells with anti-
CD3 antibody or concanavalin A, and observed EGFR phosphorylation probably through 
transactivation. Transactivation of EGFR is well documented for G-protein-coupled receptor like 
ATR-1, the receptor for angiotensin II (20). This transactivation is mediated by 
metalloproteinase-dependent release of EGFR ligands, including EGF, TGF- and HB-EGF, 
from their cell membrane-bound precursors and intermediary signaling molecules, including 
intracellular Ca
2+
, Protein Kinase C, and cytosolic tyrosine kinases such as Src kinases (21).  
The expression of EGFR and its ligands have been detected in experimental and human 
atherosclerosis (9,22). Wang et al. recently reported that EGFR engagement is important for 
macrophage proatherogenic activity, as its pharmacological inhibition reduced proinflammatory 
cytokine production, lipid uptake and oxidative stress (23). In the present study, we reported that 
global EGFR inhibition and CD4
+
 T specific deletion of EGFR reduced both atherosclerosis 
development and progression, and induced a less inflammatory plaque phenotype. 
14 
Our findings indicate that EGFR inhibitors, widely used in patients with cancer, are 
unlikely to worsen the risk of cardiovascular disease, and even more suggest that EGFR may 
constitute a novel therapeutic target in atherosclerotic disease. The recent positive results of the 
CANTOS trial (24) highlighted that modulating the immune system could be a promising 
approach to treat atherosclerosis–related cardiovascular diseases. 
Conclusions 
EGFR is expressed in human and mouse CD4
+
 T cells. EGFR pharmacological blockade 
or CD4
+
 T specific invalidation induced T cell anergy and reduced both atherosclerosis 
development and progression in mice. 
  
15 
Perspectives 
COMPETENCY IN MEDICAL KNOWLEDGE: EGFR is identified as a critical regulator in 
CD4
+
 T cell activity both in mouse and in human. EGFR pharmacological blockade using 
Erlotinib or selective invalidation in CD4
+
 T cells limited the development and the progression 
of experimental atherosclerosis. 
TRANSLATIONAL OUTLOOK: Pharmacological inhibition of EGFR may represent a 
promising new immunomodulatory treatment of cardiovascular diseases preventing the 
progression and complications of atherosclerosis. 
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Figure Legends 
Central Illustration: EGFR blockade limits pro-atherogenic activity of CD4+ T Cells. 
EGFR engagement orchestrates CD4+T cell proliferation, cytokine production and recruitment 
within atherosclerotic plaques. Pharmalogical blockade of EGFR signaling may constitute an 
attractive novel approach for the treatment of atherosclerosis. 
Figure 1: EGFR receptor expression and activation in mouse T cells. A, EGFR is expressed 
by splenocytes (green) and co-localizes with CD4
+
 T cells (Red). B, EGFR is expressed within 
mouse atherosclerotic lesions (Red) and co-localizes with CD4
+
 T cells (green). Staining was 
performed on atherosclerotic plaques (aortic sinus) from Ldlr
-/-
 mouse fed a high fat diet during 6 
weeks. C, stimulation of purified CD4
+
 T cells by coated anti-CD3 during 60 minutes induced 
focal EGFR phosphorylation that was abolished by AG-1478 (1 M). D, Flow cytometry 
quantification of Erk phosphorylation gated on CD3
+
CD4
+
 T cells after 30 minutes of anti-CD3 
(5g/ml) or Concanavalin A (10 g/ml) stimulation (N=4/group). E, Naive CD4+ T cells were 
stimulated with α-CD3/CD28 antibodies for 72h in the presence of 1µM or 10µM AG1478 
before mesuring intracellular free calcium concentration (Fura-2-AM fluorescent probe). Each 
trace is the fluorescence mean (340/380nm) of three independant experiences (10<N<40 cells 
per experience). Slope factors are calculated between 120 and 240 seconds for each experimental 
condition. *, P <0.05, ** P<0.01 *** and P<0.001. Data are expressed as median and percentiles 
(5
th
-95
th
). 
Figure 2. Effects of EGFR pharmacological inhibition on mouse T cell functions. A, in vitro 
AG-1478 induced a dose-dependent reduction of CD4
+
 T cell proliferation in response to soluble 
anti-CD3 stimulation, in the presence of CD11c
+
 dendritic cells. B, in vitro AG-1478 induced a 
dose-dependent reduction of OT-II CD4
+
 T cell proliferation after OVA stimulation in the 
20 
presence of CD11c
+
 dendritic cells. C, effects of different concentrations of AG-1478 on T cell 
apoptosis, defined as annexin V
pos 
7-AAD
neg 
cells. Purified CD4
+
 T cells were stimulated by 
coated anti-CD3 (5g/ml) or Concanavalin A (10 g/ml) and cytokine production was evaluated 
by flow cytometry (D, E) or by ELISA in the supernatants (F, G, H, I). Data are expressed as 
median and percentiles (5
th
-95
th
).  
Figure 3. EGFR pharmacological inhibition limited T cell activation in vivo and reduced 
atherosclerosis. A, protocol of pharmacological blockade of EGFR in male Ldlr
-/-
 mice 
(Erlotinib 15mg/kg/day, orally) (N=8-9/group). Cholesterolemia (B) and splenocyte number (C) 
at sacrifice. Proliferation (D) and cytokine production (ELISA, E) of purified splenic CD4
+
 T 
cells from control of erlotinib-treated animals after 48 hours of coated anti-CD3 stimulation. F, 
Quantification and representative photomicrographs of T cell infiltration in atherosclerotic 
lesions from Ldlr
-/- 
animals treated by PBS or erlotinib. N=8-9/group. G, Quantification and 
representative photomicrographs of atherosclerotic lesion size in the aortic sinus from Ldlr
-/- 
animals treated by PBS or Erlotinib. N=8-9/group. H, protocol of pharmacological blockade of 
EGFR in Ldlr
-/-
 female mice after an 8-week period of high fat diet, (Erlotinib 15mg/kg/day, 
orally) (N=7/group). I, representative photomicrographs and quantification of atherosclerotic 
lesion size along the thoracic aorta (%) from Ldlr
-/- 
animals orally treated by PBS or Erlotinib. * 
P<0.05, **, P<0.01. Data are expressed as median and percentiles (5
th
-95
th
). Adv, Adventitia. 
Figure 4: EGFR expression and functions in human T cells. A, Blood human CD4
+
 T cells 
were purified and stimulated with Concanavalin (10 g/ml) during 24 hours. EGFR is expressed 
CD4
+
 T cells after activation (fluorescent staining, Green). EGFR inhibition using tyrosine 
Kinase inhibitor (B) or neutralizing antibody (C) decreased T cell proliferation after 48 hours of 
culture at different concentrations of CD3/CD28-coated beads. Proliferation was measured by 
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incorporation of methyl-
[3H]
thymidine (N=4). (D) Pharmacological inhibition of EGFR using 
erlotinib, an EGFR TKI, blocked in vivo T cell proliferation. T cells were isolated from 3 
patients with lung cancer just before and one month after initiation of erlotinib treatment. Cells 
were stimulated with a ratio of 2 beads for 1 cell and proliferation measured by methyl-
[3H]
thymidine incorporation. *p<0.05. Bar scale 10 m. Data are expressed as median and 
percentiles (5
th
-95
th
). TKI, Tyrosine Kinase inhibitor. 
Figure 5. Selective EGFR deletion in CD4
+
 T cells induced anergy. A, In vitro, purified CD4
+
 
T cells from control Cd4-Cre/Egf-r
+/+
 (white) or Cd4-Cre/Egf-r
lox/lox
 mice (black) were 
stimulated by soluble anti-CD3 with or without co-incubation with CD11c
+
 dendritic cells 
(APC). Genetic invalidation of Egfr reduced T cell proliferation (A), IFN- (B) and IL-4 (C) 
production but had no effect on IL-10 (D) (ELISA in the supernatant). E, Representative 
examples and quantitative analysis of intracellular IFN- staining of isolated splenocytes from 
control Cd4-Cre/Egf-r
+/+
 (white) or Cd4-Cre/Egf-r
lox/lox 
mice. Plots are gated on CD4
+
 and CD8
+
 
T cells. Numbers in each quadrant indicate percentages of cells. F, representative examples of 
CD4
+
 T cell in vivo proliferation. Cd4-Cre/Egfr
+/+
 and Cd4-Cre/Egfr
lox/lox
 purified CD4
+
 T cells 
from pooled spleens and lymph nodes were labeled with CFSE fluorescent dye. Apoe
-/-
/Rag2
-/-
 
mice received 20.10
6
 CD4
+
 T cell–depleted splenocytes resupplemented with 8.106 purified 
CD4
+
 T cells from either Cd4-Cre/Egfr
+/+ 
or Cd4-CreEgfr
lox/lox
 animals. The proliferation of 
adoptively transferred cells was visualized by flow cytometric analysis of CFSE-labeled CD4
+
 T 
cells at day 10 after transfer. N=5/group, * P<0.05, **P<0.01. Data are expressed as median and 
percentiles (5
th
-95
th
). APC, Antigen Presenting Cell. 
Figure 6. Selective EGFR deletion in CD4
+
 T cells in chimeric Ldlr
-/-
 mouse model of 
atherosclerosis. A, representative examples and FACS quantification of CD4
+
 T subset. B, 
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representative examples and FACS quantification of CD4
+
CD25
+
FoxP3
+
 regulatory T cells. 
Representative examples and quantification of CD69 expression by CD4
+
 T cell (C) and 
CD44
high
 expression by CD62L
-
CD4
+
 T cells by flow cytometry (D). E, In vitro suppressive tests 
of effector CD25
-
 T cell proliferation by co-culture with CD4
+
CD25
high
 regulatory T cells 
isolated from chimeric Cd4-Cre/Egfr
+/+
/Ldlr
-/-
 or chimeric Cd4-Cre/Egf-r
lox/lox
/Ldlr
-/-
 mice. 
Purified CD4
+
 T cells from chimeric mice were stimulated by soluble anti-CD3. Genetic 
invalidation of Egfr reduced T cell proliferation (F), IFN- and IL-4 production but had no effect 
on IL-10 (G, ELISA in the supernatant). N=8-9/group, *, P<0.05. Data are expressed as median 
and percentiles (5
th
-95
th
). 
Figure 7. Selective EGFR deletion in CD4
+
 T cells reduced experimental atherosclerosis 
development. A, Representative photomicrographs of Oil Red staining and quantitative analysis 
of atherosclerotic lesion size in the aortic root of irradiated Ldlr
-/-
 mice reconstituted with bone 
marrow from either Cd4-Cre/Egfr
+/+ 
or Cd4-Cre/Egfr
lox/lox
 mice and put on a high fat diet for 4 
(N=5-6/group), 6 (N=9/group) and 12 weeks (N=9-10/group). B, Representative 
photomicrographs and quantitative analysis of T cells (CD3 staining) in atherosclerotic lesion of 
irradiated Ldlr
-/-
 mice reconstituted with bone marrow from either Cd4-Cre/Egfr
+/+ 
or Cd4-
Cre/Egfr
lox/lox
 mice and put on a high fat diet during 6 weeks. * P<0.05. 
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Online Appendix- Methods 
Cell culture and proliferation assays 
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% FCS, 0.02 mM -
mercapto-ethanol and antibiotics. To analyze T cell proliferation, 1x10
5
 CD4
+
 cells/well were co-
cultured with 10
4
 CD11c
+
 dendritic cells and soluble anti-CD3 (1g/ml) for 72 h. One Ci [3H] 
thymidine was added to each well during the last 16 h. Cells were cultured at 37°C for 72 h and 
pulsed with 1 Ci [3H] thymidine (Amersham) for the last 18 h. Thymidine incorporation was 
assessed using a TopCount NXT scintillation counter (Perkin Elmer). To analyze regulatory T 
cell functions, effectors T cells were cultured alone or co-cultured with purified regulatory T 
cells (at 1:8, 1:4, 1:2 or 1:1 ratio) in bottom-rounded 96-well microplates (0.5x10
5
 cells/well; 
total volume 200 l/well). Cells were stimulated with purified soluble CD3-specific antibody (1 
g/ml, Pharmingen) in the presence of antigen-presenting cells purified on CD11c-coated 
magnetic beads (Miltenyi Biotech). Cells were cultured at 37°C for 72 h and pulsed with 1 Ci 
[
3
H] thymidine (Amersham) for the last 18 h. Thymidine incorporation was assessed using a 
TopCount NXT scintillation counter (Perkin Elmer). 
To explore in vivo proliferation, Cd4Cre Egfr
+/+
 and Cd4Cre Egfr
lox/lox
 purified CD4
+
 T 
cells from pooled spleens and lymph nodes were labeled with CFSE fluorescent dye (5uM, 
VybrantCFDASE; Invitrogen–Molecular Probes) according to the instructions of the 
manufacturer. Apoe
-/-
/Rag2
-/-
 mice received 20x10
6
 CD4
+
 T cell–depleted splenocytes 
resupplemented with 8x10
6 
purified CD4
+
 T cells from either Cd4Cre Egfr
+/+ 
or Cd4Cre 
Egfr
lox/lox
 mice. The proliferation of adoptively transferred cells was visualized by flow 
cytometric analysis of CFSE-labeled CD4
+
 T cells at day 7 after transfer. 
2 
Human lymphocytes were isolated from blood (negative selection, Miltenyi Biotech). 
Blood samples from patients (with non-small lung cell cancer) and healthy volunteers was 
collected after informed consent, as part of the OncoHEGP clinical protocol at Georges 
Pompidou European Hospital, approved by the institutional ethics committee (CPP Ile de France 
II n°2012-08-09). Venous blood was centrifuged with a Histopaque
TM
 gradient (density: 
1.077 g/cm
3
, 30 min, 500g, 20 °C; Sigma-Aldrich, Saint Louis, US). Cells were washed twice 
with warm PBS and cell viability, as well as concentration, was determined using the trypan blue 
exclusion test. Cells were cultured in the same medium as that used for mouse cells. Specific T 
cell proliferation was induced using CD3/CD28-coated beads (Invitrogen™, Life Technologies, 
Paisley, UK) with different Bead/T cell ratio. EGFR engagement was blocked using the specific 
pharmacological inhibitor AG-1478 (Calbiochem™, Merck Millipore, Darmstadt, Germany). 
We also used the specific EGFR mAb, Erbitux (Cetuximab®, Merk Sorono, 1μg/mL), which 
links the EGFR extracellular domain and prevents binding of ligands. 
Cytosolic calcium recording 
Intracellular Ca2+ activity was determined as previously described (1). Briefly, CD4+ T 
cells were loaded at 1x10
6
/mL with Fura-2-AM (5µM, with 0.015% Pluronic F127 in RPMI 
medium) (Molecular Probes, ThermoFisher Scientific) for 30 min at room temperature, washed 
and then resuspended in RPMI medium. Cells were attached to poly(L)-lysine-coated petri dish 
(Sigma-Aldrich) for 20 min at 37°C and Fura-2 dual excitation was accomplished using 340- 
380nm excitation filters at 5 seconds intervals. Cells were then perfused with the bath solution in 
the presence or absence of 2 mM extracellular Ca2+ and stimulated with 5µg/mL of anti-CD3 
antibody (BD biosciences). Variation of fluorescence ratio reveal intracellular variation of free 
3 
cytosolic calcium concentration. Data were analyzed using Leica DMI 6000 inverted microscope 
using MetaFluor Software (Leica, Wetzlar, Germany). 
Western Blot 
After extraction from isolated CD4
+
 T cells with RIPA buffer, proteins were quantified 
using a BCA protein assay kit (iNtRON Biotechnology). Equal amounts of proteins were loaded 
onto sodium dodecyl sulfate-polyacrylamide electrophoresis gels (4%-12% Bis-Tris Criterion 
XT gels, Biorad) for separation and transferred onto polyvinylidene difluoride membranes. 
Membranes were blocked with milk and probed with different antibodies: anti-Akt (Cell 
Signaling Technology, C67E7), anti-Phospho Akt (Cell Signaling Technology, D9E), anti-
ERK1/2 (Cell Signaling Technology, 137F5), anti-Phospho ERK T202/Y204 (Cell Signaling 
Technology, D13.14.4E) and anti-TUBA/a-tubulin (Abcam, ab6160).  Protein loading was 
monitored using an anti-tubulin antibody (Abcam, Inc.). The membranes were then probed with 
horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, 7074 and 
7076) and the bands were visualized by enhanced chemiluminescence (Clarity Western ECL 
substrate; Bio-Rad, 170–5061). Antigens were revealed by enhanced chemiluminescence 
(Supersignal West Pico; Pierce) and detected on a LAS-4000 imaging system (Fuji, LAS4000, 
Burlington, NJ, USA). Densitometric analysis with ImageJ software was used for quantification. 
Flow cytometry 
Cells were labeled with APC-conjugated anti-CD3 (145-2C11), FITC- or PE-Cy7-
conjugated anti-CD4 (RM4-5), APC-conjugated anti-CD25 (PC61.5), PE-Cy7-conjugated anti-
CD11b (M1/70), PE-conjugated anti-Foxp3 (PFJK-16s), eFluor 450-conjugated anti-CD62L 
(MEL-14) and APC-conjugated anti-CD44 (IM7) mAbs from eBioscience. PE-conjugated anti-
Ly6G (1A8), Alexa Fluor 488-conjugated anti-CD11b (M1/70), APC-conjugated F4/80 (BM8) 
4 
FITC-conjugated anti-CD19 (1D3), Alexa Fluor 700-conjugated anti-CD8 (53-6.7), APC-
conjugated anti-IFN (XMG1.2), PE-conjugated anti-IL10 (JES-16E3), Alexa Fluor 647-
conjugated anti-ERK1/2 (pT202/pY204) were from BD Biosciences. Alexa fluor 647-conjugated 
anti-7/4 was from Serotec. For blood staining, erythrocytes were lyzed using BD FACS lysis 
solution (BD Biosciences). For intracellular cytokine staining, lymphocytes were stimulated in 
vitro with leukocyte activation cocktail (BD Biosciences) according to manufacturer’s 
instructions for 4 h. Surface staining was performed before permeabilization using Foxp3 
staining buffer kit (eBioscience) and intracellular staining. Forward scatter (FSC) and side scatter 
(SSC) were used to gate live cells excluding RBC, debris, and cell aggregates in total 
splenocytes. Cells were analyzed using a BD CantoII or BD LSRII flow cytometer (BD 
Biosciences). 
Apoptosis susceptibility of purified CD4
+
 T cells was determined using the apoptosis 
detection kit Annexin V- (FITC) and 7AAD (APC) (BD Biosciences, San Jose, CA, US) 
according to the manufacturer's instructions. 
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Online Figure Legends 
Online Figure 1. EGFR pharmacological inhibition reduced ERK phosphorylation 
Online Figure 2. No effect of EGFR pharmacological inhibition on CD4+ T cell 
morphology. 
Online Figure 3. EGFR pharmacological inhibition reduced IL-2 production by CD4+ T 
cells. 
Online Figure 4. Erlotinib treatment had no effect on animal weight but induced a 
reduction of spleen size. 
Online Figure 5. Erlotinib treatment reduced CD4+ T cell activation 
Online Figure 6. Erlotinib treatment blocked atherosclerosis progression. 
Online Figure 7. Absence of EGFR expression on CD4+ T cells from Cd4 Cre EgfrLox/lox 
mice. 
Online Figure 8. EGFR deficiency reduced CD4+ T cell apoptosis. 
Online Figure 9. EGFR deficiency had no impact on cholesterolemia. 
Online Figure 10. EGFR deficiency in CD4+ T cells had no impact on macrophage content. 
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